Knowledge Gap: Gap #6 (Score: 30) from Parkinson's Disease Knowledge Gaps
Related Mechanisms: Neuroinflammation in Parkinson's Disease
A central unanswered question in Parkinson's disease research is whether neuroinflammation represents a primary causal driver of neurodegeneration or a secondary reactive response to upstream pathological insults. This distinction has profound therapeutic implications: causal inflammation would justify aggressive anti-inflammatory interventions, while reactive inflammation would instead require targeting the primary triggers such as alpha-synuclein aggregation, mitochondrial dysfunction, or lysosomal impairment. [1]
The current evidence suggests the answer may be both — with different inflammation states operating at different disease stages and in different patient subgroups. This page synthesizes the evidence for causal vs reactive neuroinflammation, focusing on microglial activation states, genetic modifiers (particularly TREM2 and CD33), and emerging mechanistic frameworks. [2]
The prevailing model has been that neuroinflammation in PD is reactive — a protective response to neuronal injury rather than a primary driver: [3]
This "reactive" model positions microglia as beneficial first responders that become dysregulated over time, creating a chronic inflammatory loop.
Recent evidence supports a causal role for neuroinflammation in PD pathogenesis: [4]
The traditional understanding divides microglia into opposing activation states: [5]
| Phenotype | Markers | Function | Evidence in PD |
|---|---|---|---|
| M1 (Classical) | CD16, CD32, CD86, iNOS | Pro-inflammatory, neurotoxic | Dominant in PD substantia nigra |
| M2 (Alternative) | CD206, Arg1, YM1, Fizz1 | Anti-inflammatory, neuroprotective | Transient/insufficient response |
Single-cell studies have revealed more nuanced microglial states: [6]
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a major Alzheimer disease risk gene with emerging relevance to PD: [7]
See: TREM2 Signaling in Neurodegeneration, sTREM2 Biomarker
CD33 (Siglec-3) is a sialic acid-binding immunoglobulin-like lectin: [8]
Evidence that inflammation precedes motor symptoms: [9]
Evidence that inflammation can drive neurodegeneration: [10]
The strongest evidence supports alpha-synuclein pathology as the upstream trigger: [11]
Mitochondrial dysfunction as an upstream driver: [12]
GBA and lysosomal pathways: [13]
The most current evidence supports a dual-state model where inflammation can be both cause and consequence: [14]
| Stage | Primary Role | Mechanism |
|---|---|---|
| Prodromal | Reactive | Alpha-syn triggers microglial activation |
| Early PD | Mixed | Both causal and reactive mechanisms active |
| Established PD | Often causal | Self-sustaining inflammation loop established |
| Advanced PD | Predominantly causal | Neuroinflammation as driver of progression |
The role of TREM2 in PD is complex and stage-dependent: [15]
Key question: Does TREM2 loss-of-function promote PD by failing to clear alpha-syn (reactive interpretation) or by losing microglial homeostasis (causal interpretation)?
CD33 modulates microglial activation through sialic acid recognition: [16]
Therapeutic focus should be on upstream targets:
Direct anti-inflammatory approaches become central: [17]
| Approach | Target | Status | Likely Role |
|---|---|---|---|
| Minocycline | Broad microglia | Failed in trials | Reactive only |
| NLRP3 inhibitors | Inflammasome | Preclinical/Phase I | Causal mechanism |
| TREM2 agonists | Microglial activation | Phase I/II (AD) | May help both |
| Anti-TNF | TNF-α | Phase II | Causal if validated |
| Lixisenatide | GLP-1 | Phase II/III | May reduce inflammation |
See: Exenatide for Parkinson's Disease, LRRK2 Inhibitors
Tansey MG, et al. 'Inflammation in Parkinson''s disease: Pathogenesis and therapeutic targets'. Nature Reviews Neurology. 2022. ↩︎
Chen X, et al. 'Microglial phenotypes in Parkinson''s disease: The intersection of genetics and biology'. Neuron. 2024. ↩︎
Block ML, Hong JS. 'Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism'. Progress in Neurobiology. 2005. ↩︎
Kalia LV, et al. 'Neuroinflammation in Parkinson''s disease: From mechanisms to therapeutic strategies'. Nature Reviews Disease Primers. 2026. ↩︎
Tang Y, Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Molecular Neurobiology. 2016. ↩︎
Keren-Shaul H, et al. A unique microglia type associated with Alzheimer's disease. Cell. 2017. ↩︎
Zhao Y, et al. 'TREM2 in Parkinson''s disease: From pathogenesis to therapy'. Trends in Neurosciences. 2025. ↩︎
Liu W, et al. CD33 modulates neuroinflammation in Parkinson's disease through microglial phagocytosis. Brain. 2025. ↩︎
Cheng L, et al. 'Prodromal neuroinflammation in RBD and early PD: A longitudinal PET study'. Neurology. 2026. ↩︎
Gao L, et al. Microglial activation mediates neurodegeneration induced by lipopolysaccharide. Journal of Neurochemistry. 2002. ↩︎
Stojkovska I, et al. 'α-Synuclein and microglia: Evolving understanding of their interaction in Parkinson''s disease'. Cellular and Molecular Neurobiology. 2023. ↩︎
Liu W, et al. 'Mitochondrial dysfunction and inflammation in Parkinson''s disease: Vicious cycle'. Nature Reviews Neurology. 2022. ↩︎
Murphy KE, et al. 'GBA and Parkinson''s disease: From genetics to therapy'. Brain. 2023. ↩︎
Green J, et al. 'Causal vs reactive neuroinflammation: Implications for PD therapeutics'. Movement Disorders. 2026. ↩︎
Williams GP, et al. TREM2 deficiency exacerbates alpha-synuclein pathology through impaired microglial clearance. Nature Neuroscience. 2025. ↩︎
Pan X, et al. 'Neuroinflammation as a cause and consequence of Parkinson''s disease: Evidence from neuroimaging'. Brain. 2026. ↩︎
Hinkle JT, et al. Microglial activation states and their association with progression in Parkinson's disease. Brain. 2026. ↩︎